Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-01397 | Chimmitecan | 185425-25-6 |
| Chimmitecan is a potent topoisomerase I inhibitor. Chimmitecan is also an active metabolite of simmitecan. Chimmitecan displays outstanding activity in vitro and in vivo. The substitution at the 9-position benefits chimmitecan a salient anti-MDR activity, stability in human serum albumin, improved solubility, and oral availability, which might favorably promise its therapeutic potential in clinical settings. | Inquiry | |
| BADC-00028 | DOXO-EMCH | 151038-96-9 |
| DOXO-EMCH is an albumin-binding prodrug of doxorubicin, which is an anthracycline antibiotic with anti-Gram-positive bacterial activity and a broad antitumor spectrum. | Inquiry | |
| BADC-01380 | SG2057 | 260417-62-7 |
| SG2057 is a pentyldioxy linked PBD dimer which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts, and also mono-adducts depending on sequence. SG2057 has multilog differential in vitro cytotoxicity against a panel of human tumour cell lines with a mean GI(50) of 212 pM. The agent is highly efficient at producing DNA interstrand cross-links in cells which form rapidly and persist over a 48h period. Cures were obtained in a LOX-IMVI melanoma model following a single administration and dose-dependent activity, including regression responses, observed in SKOV-3 ovarian and HL-60 promyelocytic leukemia models following repeat dose schedules. In the advanced stage LS174T model, SG2057 administered either as a single dose, or in two repeat dose schedules, was superior to irinotecan. SG2057 is therefore a highly active antitumor agent, with more potent in vitro activity and superior in vivo activity to SG2000. | Inquiry | |
| BADC-00346 | Maytansine | 35846-53-8 |
| Maitansine, a cytotoxic agent, inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site. | Inquiry | |
| BADC-00027 | INNO-206 | 1361644-26-9 |
| INNO-206 (Aldoxorubicin) is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. | Inquiry | |
| BADC-00026 | Mc-MMAD | 1401963-15-2 |
| Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAD is a protective group (maleimidocaproyl) -conjugated MMAD. | Inquiry | |
| BADC-00320 | MMAF Hydrochloride | 1415246-68-2 |
| MMAF Hydrochloride, a synthetic antineoplastic agent, is a tubulin polymerization inhibitor that inhibits cell division by blocking the polymerization of tubulin. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. | Inquiry | |
| BADC-00032 | PF-06380101 | 1436391-86-4 |
| PF-06380101 is a novel cytotoxic Dolastatin 10 analogue; with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs. | Inquiry | |
| BADC-00324 | MMAE | 474645-27-7 |
| Monomethyl Auristatin E (MMAE) is a synthetic analog of dolastatin 10 that similarly inhibits tubulin polymerization and exhibits potent cytotoxicity. It is commonly conjugated with monoclonal antibodies directed at antigens specific to cancer cells for tumor-directed cytotoxicity. | Inquiry | |
| BADC-00318 | MMAF | 745017-94-1 |
| Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. | Inquiry | |
| BADC-01391 | Methotrexate monohydrate | 6745-93-3 |
| Methotrexate monohydrate is a DHhF reductase inhibitor that inhibits the enzyme dihydrofolate reductase and DNA synthesis. Therefore it is used to treat various cancers. | Inquiry | |
| BADC-00188 | Auristatin E | 160800-57-7 |
| Auristatin E is a synthetic analog of dolastatin 10. Auristatin E is a highly potent antimitotic agent.Auristatin E inhibits tubulin polymerization. Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity. | Inquiry | |
| BADC-00045 | Auristatin F | 163768-50-1 |
| Auristatin F, a synthetic analog of dolastatin 10, is a cytotoxic tubulin modifier with potent and selective antitumor activity. It is an MMAF analog and cytotoxin in Antibody-drug conjugates. | Inquiry | |
| BADC-00310 | MMAD hydrochloride | 173441-26-4 |
| Monomethyl auristatin D Hcl (MMAD Hcl), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. | Inquiry | |
| BADC-00033 | PNU-159682 | 202350-68-3 |
| PNU-159682 is a major active metabolite of nemorubicin (MMDX) in human liver microsomes. It is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity, and shows >3,000-fold cytotoxic than its parent compound (MMDX and doxorubicin). It is a more potent and well tolerated ADC cytotoxin than doxorubicin. | Inquiry | |
| BADC-00309 | MMAD | 203849-91-6 |
| Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload and antibody drug conjugate. | Inquiry | |
| BADC-00035 | Taltobulin trifluoroacetate | 228266-41-9 |
| Taltobulin trifluoroacetate is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin trifluoroacetate inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis. | Inquiry | |
| BADC-00043 | Daun02 | 290304-24-4 |
| Daun02 is a daunorubicin b-galactoside prodrug for use in conjunction. | Inquiry | |
| BADC-00290 | Lycorine HCl | 2188-68-3 |
| Lycorine is a toxic crystalline alkaloid found in various Amaryllidaceae species, such as the cultivated bush lily , surprise lilies, and daffodils. It may be highly poisonous, or even lethal, when ingested in certain quantities. Symptoms of lycorine toxicity are vomiting, diarrhea, and convulsions. | Inquiry | |
| BADC-00327 | Idarubicin | 58957-92-9 |
| Idarubicin is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL. | Inquiry |
